Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 2/20 | 0.50 |
| ▸ | CDK8 | P49336 | 2/20 | 0.50 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8009419 | 0.90 | CCNC (0.53) | CCNCCDK8HASPINSIGMAR1NPY5R | |
| SCHEMBL14543925 | 0.82 | SIGMAR1 (0.70) | SIGMAR1NPY5RSSTR5HRH3 | |
| SCHEMBL9963270 | 0.82 | HSD11B1 (0.49) | HSD11B1SIGMAR1NPY5R | |
| SCHEMBL6820764 | 0.77 | NPY5R (0.48) | HSD11B1SIGMAR1NPY5R | |
| SCHEMBL15710521 | 0.77 | NPY5R (0.48) | HSD11B1SIGMAR1NPY5R | |
| SCHEMBL14349511 | 0.77 | NPY5R (0.48) | HSD11B1NPY5R | |
| SCHEMBL13710674 | 0.77 | NPY5R (0.54) | HSD11B1NPY5R | |
| SCHEMBL6820751 | 0.74 | NPY5R (0.56) | HSD11B1NPY5R | |
| SCHEMBL17804385 | 0.74 | NPY5R (0.54) | HSD11B1NPY5R | |
| SCHEMBL6820752 | 0.74 | NPY5R (0.56) | HSD11B1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288409-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288409-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2009102574-A1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, OPRL1 | CCNC 3447/4885CDK8 3889/4885HASPIN 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.